Drugnews

Company Services

Make your science, clinical progress, and business strategy understandable to professional readers.

Drugnews is a reader-first biotech business-analysis media platform. We also work with public companies, biotech startups, pharma companies, CDMOs, and medical-technology teams to turn R&D progress, clinical evidence, licensing logic, and capital-market stories into clear company narratives.

Client Experience

Past collaborators

How we help

All collaboration content is built on public information, company-approved disclosure, and professional research frameworks.

Company research and feature articles

We turn pipelines, platforms, clinical positioning, competitive landscapes, and business models into long-form analysis that supports reader judgment.

IR and capital-market narratives

We translate clinical, CMC, regulatory, commercialization, and peer-comparison information into value logic investors can follow.

Social content and distribution

We adapt long-form analysis into readable social summaries, visual posts, and key-message cards that lead back to clear business judgment.

Events and interviews

We design interviews, online briefings, event recaps, and follow-up articles that help professional readers understand a company's market position.

Company-service FAQ

We help companies make value logic clear, not turn analysis into advertising.

The goal is to help professional readers understand clinical evidence, business strategy, and capital-market signals.

Who should use Drugnews company services?

Drugnews company services are designed for public biotech companies, startups, pharma companies, CDMOs, medical-technology companies, and IR teams that need to explain clinical evidence, technology platforms, licensing transactions, or commercialization strategy more clearly.

Is this advertising or editorial analysis?

The goal is not to turn a company deck into advertising. Drugnews uses public information, company-approved disclosure, and research frameworks to help professional readers understand the company's value logic, risks, and catalysts.

Can Drugnews help with English content for global readers?

Yes. Drugnews maintains English articles and English service pages, and can help turn Chinese company stories into clearer English narratives for international investors and industry readers.

How does a company start a collaboration?

A company can submit the collaboration form or email drugnews.dr.pan@gmail.com. Drugnews first clarifies the market question, available disclosure, target readers, and suitable content format.